Developer docs
API playgroundTry for free, no card

Search company profiles

ADIENNE

Full company profile

uuid000bg78

Namestring
ADIENNE
Websiteurl
adienne.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

ADIENNE is a privately held biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The company operates with a headcount in the 51–100 range and is led by founder and president Antonio Francesco Di Naro, indicating a founder-controlled governance structure that has persisted across the company's two-decade operating history.

The company's website (adienne.com) was inaccessible during data collection, presenting only a loading/verification message; consequently, the specific therapeutic areas, product portfolio, pipeline stage, manufacturing capabilities, and target indications of ADIENNE could not be verified from the primary source. Based on its firmographic profile (Swiss domicile, ~20-year operating history, biotech-relevant headcount, founder-led), ADIENNE conforms to the archetype of a European specialty biopharma focused on niche or rare-disease therapeutics, though no named products, candidates, or technology platform could be extracted from the input.

ADIENNE is a for-profit private company (no public ticker is recorded). No funding rounds, ownership structure, partnerships, or customer relationships are documented in the available input, and no information about revenue model, pricing, go-to-market strategy, or end markets could be confirmed. Investors examining ADIENNE should treat the firmographic profile as the only confirmed identity and pursue direct company outreach to validate product strategy, pipeline, and commercial status.

Short descriptiontext

ADIENNE is a privately held, founder-led biopharmaceutical company founded in 2004 and headquartered in Lugano, Switzerland, operating with 51–100 employees. Specific therapeutic focus, products, and pipeline were not retrievable from available data.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLugano, Switzerland
HQ citystring
Lugano
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biopharmaceutical development, pharmaceutical manufacturing, specialty drug products, clinical-stage therapeutics, biologics and drugs
Industry1 code
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ADIENNE is a biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The firm develops and manufactures pharmaceutical products, operating with a headcount of 51-100 employees. It functions as a for-profit private biopharma entity focused on producing drug products for the healthcare market.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

European specialty pharma with a dedicated rare-disease business unit, comparable to ADIENNE in targeting niche specialty therapeutics with premium pricing models and EMEA-led commercialization.

TypeBroad incumbent
Description

Historically a leading specialty/rare-disease biopharma with a focus on small patient populations and premium pricing — relevant comparable for ADIENNE's specialty therapeutic model.

3Gentium (now Jazz Pharmaceuticals)
TypeDirect peer
Description

Originally an Italian specialty biopharma developing defibrotide for hepatic veno-occlusive disease — directly comparable to ADIENNE's specialty pharma focus and therapeutic category, now operating under Jazz.

4MolMed
TypeDirect peer
Description

European biopharma developing specialty therapeutics including cell & gene therapies for rare and serious diseases, with comparable therapeutic focus and European specialty pharma positioning.

TypeDirect peer
Description

Swiss-based specialty biopharmaceutical company focused on oncology and supportive care, headquartered near Lugano. Closely comparable in geography, therapeutic focus, and private-company specialty pharma positioning.

6Erytech Pharma
TypeEmerging player
Description

European specialty biopharma developing niche oncology and rare-disease therapeutics. Comparable as a smaller, specialty-focused peer with overlapping therapeutic-area ambitions.

TypeBroad incumbent
Description

Global rare-disease biopharma specializing in highly targeted therapies for small patient populations. Comparable to ADIENNE in product economics, regulatory complexity, and specialty commercial model.

TypeBroad incumbent
Description

Global specialty biopharma focused on rare diseases and specialty therapeutics, including the historical defibrotide franchise that overlaps directly with ADIENNE's therapeutic areas. Comparable as a specialty pharma commercializer with a similar product-category footprint.

TypeDirect peer
Description

Swiss specialty biopharma headquartered in the same regional cluster as ADIENNE, focused on niche therapeutics including hematology/cardio-renal. Highly comparable on geography, scale, and therapeutic category.

TypeBroad incumbent
Description

European specialty biopharma focused on rare diseases and specialty care, offering a relevant comparable for revenue model, regulatory pathway, and target patient population dynamics.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ADIENNE

Biopharmaceuticalsadienne.com

ADIENNE is a privately held, founder-led biopharmaceutical company founded in 2004 and headquartered in Lugano, Switzerland, operating with 51–100 employees. Specific therapeutic focus, products, and pipeline were not retrievable from available data.

What ADIENNE does

ADIENNE is a privately held biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The company operates with a headcount in the 51–100 range and is led by founder and president Antonio Francesco Di Naro, indicating a founder-controlled governance structure that has persisted across the company's two-decade operating history.

The company's website (adienne.com) was inaccessible during data collection, presenting only a loading/verification message; consequently, the specific therapeutic areas, product portfolio, pipeline stage, manufacturing capabilities, and target indications of ADIENNE could not be verified from the primary source. Based on its firmographic profile (Swiss domicile, ~20-year operating history, biotech-relevant headcount, founder-led), ADIENNE conforms to the archetype of a European specialty biopharma focused on niche or rare-disease therapeutics, though no named products, candidates, or technology platform could be extracted from the input.

ADIENNE is a for-profit private company (no public ticker is recorded). No funding rounds, ownership structure, partnerships, or customer relationships are documented in the available input, and no information about revenue model, pricing, go-to-market strategy, or end markets could be confirmed. Investors examining ADIENNE should treat the firmographic profile as the only confirmed identity and pursue direct company outreach to validate product strategy, pipeline, and commercial status.

ADIENNE firmographics

Firmographics
Name
ADIENNE
Website
https://adienne.com
Company type
Private
Founded year
2004
Headcount range
101–250 employees
Short description
ADIENNE is a privately held, founder-led biopharmaceutical company founded in 2004 and headquartered in Lugano, Switzerland, operating with 51–100 employees. Specific therapeutic focus, products, and pipeline were not retrievable from available data.
Ownership category
akta.pro rank

ADIENNE industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Biopharmaceutical development
  • Pharmaceutical manufacturing
  • Specialty drug products
  • Clinical-stage therapeutics
  • Biologics and drugs

Where ADIENNE is headquartered

Location

Headquarters

HQ city
Lugano
HQ country
Switzerland
HQ region
Europe

Markets served

ADIENNE business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

ADIENNE product offering

Product offering

Core offering

ADIENNE is a biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The firm develops and manufactures pharmaceutical products, operating with a headcount of 51-100 employees. It functions as a for-profit private biopharma entity focused on producing drug products for the healthcare market.

Differentiator

Problem solved

Functional benefit

Companies that use ADIENNE

Customer profile

Ideal customer profiles1 record

ADIENNE technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ADIENNE partnerships and signals

Strategic signal

Recent moves1 record

ADIENNE competitors and assessment

Company assessment

Broad incumbents

  • Recordati Rare Diseases: European specialty pharma with a dedicated rare-disease business unit, comparable to ADIENNE in targeting niche specialty therapeutics with premium pricing models and EMEA-led commercialization.
  • Shire (now Takeda): Historically a leading specialty/rare-disease biopharma with a focus on small patient populations and premium pricing — relevant comparable for ADIENNE's specialty therapeutic model.
  • Alexion (AstraZeneca Rare Disease): Global rare-disease biopharma specializing in highly targeted therapies for small patient populations. Comparable to ADIENNE in product economics, regulatory complexity, and specialty commercial model.
  • Jazz Pharmaceuticals: Global specialty biopharma focused on rare diseases and specialty therapeutics, including the historical defibrotide franchise that overlaps directly with ADIENNE's therapeutic areas. Comparable as a specialty pharma commercializer with a similar product-category footprint.
  • Swedish Orphan Biovitrum (Sobi): European specialty biopharma focused on rare diseases and specialty care, offering a relevant comparable for revenue model, regulatory pathway, and target patient population dynamics.

Direct peers

  • Gentium (now Jazz Pharmaceuticals): Originally an Italian specialty biopharma developing defibrotide for hepatic veno-occlusive disease — directly comparable to ADIENNE's specialty pharma focus and therapeutic category, now operating under Jazz.
  • MolMed: European biopharma developing specialty therapeutics including cell & gene therapies for rare and serious diseases, with comparable therapeutic focus and European specialty pharma positioning.
  • Helsinn Group: Swiss-based specialty biopharmaceutical company focused on oncology and supportive care, headquartered near Lugano. Closely comparable in geography, therapeutic focus, and private-company specialty pharma positioning.
  • Vifor Pharma (CSL Vifor): Swiss specialty biopharma headquartered in the same regional cluster as ADIENNE, focused on niche therapeutics including hematology/cardio-renal. Highly comparable on geography, scale, and therapeutic category.

Emerging players

  • Erytech Pharma: European specialty biopharma developing niche oncology and rare-disease therapeutics. Comparable as a smaller, specialty-focused peer with overlapping therapeutic-area ambitions.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

ADIENNE social profiles

Digital presence

ADIENNE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ADIENNE leadership team

Management profile

Number of profiles

Profiles1 record

ADIENNE funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ADIENNE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADIENNE

What does ADIENNE do?

ADIENNE is a biopharmaceutical company headquartered in Lugano, Switzerland, founded in 2004. The firm develops and manufactures pharmaceutical products, operating with a headcount of 51-100 employees. It functions as a for-profit private biopharma entity focused on producing drug products for the healthcare market.

When was ADIENNE founded?

ADIENNE was founded in 2004. It employs 101 to 250 people.

Where is ADIENNE based?

ADIENNE is headquartered in Lugano, Switzerland, in the Europe region.

Who are ADIENNE's main competitors?

Broad incumbents on record are Recordati Rare Diseases, Shire (now Takeda), Alexion (AstraZeneca Rare Disease), Jazz Pharmaceuticals and Swedish Orphan Biovitrum (Sobi). Direct peers are Gentium (now Jazz Pharmaceuticals), MolMed, Helsinn Group and Vifor Pharma (CSL Vifor). Erytech Pharma is listed as an emerging player.

Does ADIENNE have an API?

No public API is recorded for ADIENNE.

What industry is ADIENNE in?

ADIENNE's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales